Select the search type
  • Site
  • Web
Latest News and Events
Author: Created: Mon, 28 Feb 2011 11:19:36 GMT
By host on Thu, 28 Feb 2013 16:57:25 GMT
CoAcS ran two one-day workshops at Khartoum University, Sudan on 26/27th February. We were invited to show how systems can contribute to patient safety and to raise the profile of pharmacy services.
By host on Thu, 01 Nov 2012 12:16:32 GMT
Rare opportunity! CoAcS are looking for a Junior Software Developer to join our team in Bath.
By host on Thu, 12 Jul 2012 09:30:07 GMT
Prof. Sir Kent Woods, Chief Executive of the MHRA, has written a letter to all Trust CEOs encouraging them to use MiDatabank for Yellow Card reporting.
By host on Thu, 05 Jul 2012 17:28:00 GMT
MiDatabank is being used to handle enquiries from patients calling the rheumatology helpline at the Chapel Allerton hospital in Leeds. Launched on 18th June 2012, the system has already handled over 500 enquiries in three weeks.
By host on Mon, 25 Jun 2012 17:37:12 GMT
In Australia, the National Prescribing Service (NPS) will now use MiDatabank's new reporting capability to electronically submit ADRs.
By host on Tue, 17 Apr 2012 16:18:06 GMT
The Ambassador of the Federal Democratic Republic of Ethiopia visited Bath and during a meeting in the Mayor's Parlour in the Guildhall Dr Stephen Moss, Managing Director of CoAcS Ltd discussed export of pharmaceutical products from the UK into Ethiopia. A further round table meeting will be arranged for the near future.
By host on Thu, 01 Mar 2012 15:58:06 GMT
The ePMRx patient records and labeling system has been sold into the Yiaco pharmacy chain in Kuwait.
By host on Sun, 19 Feb 2012 13:46:13 GMT
The re-vamped and re-organised CoAcS website has been launched! You're browsing it now...
By host on Tue, 17 Jan 2012 08:51:19 GMT
The new CoAcS corporate brochure was printed and made available in time for Arab Health conference in Dubai.
By host on Tue, 06 Dec 2011 16:19:41 GMT
Another international pharmaceutical company has chosen MiDatabank i to log medicines enquiries for its ‘special’ drugs.